At the time of writing, Fate Therapeutics Inc [FATE] stock is trading at $1.05, up 2.94%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FATE shares have gain 0.96% over the last week, with a monthly amount drifted -31.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on October 31, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, Wedbush upgraded its rating to Outperform on October 27, 2025, and kept the price target unchanged to $7. On November 18, 2024, upgrade upgraded it’s rating to Neutral. Piper Sandler upgraded its rating to a Overweight and increased its price target to $6 on June 17, 2024. H.C. Wainwright downgraded its rating to Neutral for this stock on January 24, 2023, and downed its price target to $7. In a note dated January 06, 2023, Wedbush downgraded a Neutral rating on this stock and revised its target price from $42 to $7.
For the past year, the stock price of Fate Therapeutics Inc fluctuated between $0.66 and $3.43. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $1.05 at the most recent close of the market. An investor can expect a potential return of 3661.9% based on the average FATE price forecast.
Analyzing the FATE fundamentals
According to Fate Therapeutics Inc [NASDAQ:FATE], the company’s sales were 7.14M for trailing twelve months, which represents an -43.36% plunge. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -24.48%, Pretax Profit Margin comes in at -21.87%, and Net Profit Margin reading is -21.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.57 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9950 points at the first support level, and at 0.9400 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0900, and for the 2nd resistance point, it is at 1.1300.
Ratios To Look Out For
It is important to note that Fate Therapeutics Inc [NASDAQ:FATE] has a current ratio of 7.87. In addition, the Quick Ratio stands at 7.87 and the Cash Ratio stands at 1.45. Considering the valuation of this stock, the price to sales ratio is 16.96, the price to book ratio is 0.52.
Transactions by insiders
Recent insider trading involved TAHL CINDY, that happened on Aug 04 ’25 when 9037.0 shares were sold. President and CEO, Valamehr Bahram completed a deal on Aug 04 ’25 to sell 14466.0 shares. Meanwhile, Officer TAHL CINDY bought 9037.0 shares on Aug 04 ’25.
